These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25442812)

  • 1. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
    Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
    Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
    World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of palliative chemotherapy and best supportive care on overall survival and length of hospitalization in patients with incurable Cancer: a 4-year single institution experience in Japan.
    Murakawa Y; Sakayori M; Otsuka K
    BMC Palliat Care; 2019 Jun; 18(1):45. PubMed ID: 31159782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
    Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status.
    Fiorin de Vasconcellos V; Rcc Bonadio R; Avanço G; Negrão MV; Pimenta Riechelmann R
    BMC Palliat Care; 2019 May; 18(1):42. PubMed ID: 31109330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?
    Baldotto CS; Cronemberger EH; de Biasi P; Zamboni M; Sousa A; Zukin M; Small IA; Ferreira CG
    Support Care Cancer; 2012 Nov; 20(11):2721-7. PubMed ID: 22322592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
    Shuch B; La Rochelle JC; Wu J; Klatte T; Riggs SB; Kabbinavar F; Belldegrun AS; Pantuck AJ
    Cancer; 2008 Sep; 113(6):1324-31. PubMed ID: 18661529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation analysis between abundance of K-ras mutation in plasma free DNA and its correlation with clinical outcome and prognosis in patients with metastatic colorectal cancer].
    Bai YQ; Liu XJ; Wang Y; Ge FJ; Zhao CH; Fu YL; Lin L; Xu JM
    Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):666-71. PubMed ID: 24332053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.
    Crumley AB; Stuart RC; McKernan M; McDonald AC; McMillan DC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e325-9. PubMed ID: 17645468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC).
    Berretta M; Zanet E; Nasti G; Lleshi A; Frustaci S; Fiorica F; Bearz A; Talamini R; Lestuzzi C; Lazzarini R; Fisichella R; Cannizzaro R; Iaffaioli RV; Berretta S; Tirelli U
    Arch Gerontol Geriatr; 2012; 55(2):271-5. PubMed ID: 21937127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
    Kim MS; Chung M; Ahn JB; Kim CW; Cho MS; Shin SJ; Baek SJ; Hur H; Min BS; Baik SH; Kim NK
    J Surg Oncol; 2014 Aug; 110(2):214-21. PubMed ID: 24668581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
    Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
    Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials.
    Abdel-Rahman O
    Int J Colorectal Dis; 2019 Dec; 34(12):2143-2150. PubMed ID: 31732876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
    Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
    J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy.
    Aziz A; Fritsche HM; Gakis G; Kluth LA; Hassan Fa; Engel O; Dahlem R; Otto W; Gierth M; Denzinger S; Schwentner C; Stenzl A; Shariat SF; Fisch M; Burger M; Rink M
    Urol Oncol; 2014 Nov; 32(8):1141-50. PubMed ID: 24856977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
    Spigel DR; Greco FA; Waterhouse D; Shipley D; Lane CM; Vazquez ER; Clark BL; Infante JR; Bendell JC; Burris HA; Hainsworth JD
    Clin Adv Hematol Oncol; 2010 Jul; 8(7):480-5, 498. PubMed ID: 20864916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
    Gouverneur A; Coutureau J; Jové J; Rouyer M; Grelaud A; Duc S; Gérard S; Smith D; Ravaud A; Droz C; Bernard MA; Lassalle R; Forrier-Réglat A; Noize P;
    Clin Colorectal Cancer; 2019 Mar; 18(1):e150-e162. PubMed ID: 30630730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-related toxicity and supportive care in metastatic colorectal cancer.
    Zafar SY; Marcello JE; Wheeler JL; Rowe KL; Morse MA; Herndon JE; Abernethy AP
    J Support Oncol; 2010; 8(1):15-20. PubMed ID: 20235419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.